AVITA Medical Beheer

Beheer criteriumcontroles 1/4

De CEO AVITA Medical is Jim Corbett, benoemd in Sep2022, heeft een ambtstermijn van 2.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.07M, bestaande uit 30.2% salaris en 69.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.033% van de aandelen van het bedrijf, ter waarde A$ 173.97K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 6.1 jaar.

Belangrijke informatie

Jim Corbett

Algemeen directeur

US$2.1m

Totale compensatie

Percentage CEO-salaris	30.2%
Dienstverband CEO	2.2yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	6.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jim Corbett's beloning veranderd ten opzichte van AVITA Medical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$57m
Jun 30 2024	n/a	n/a	-US$50m
Mar 31 2024	n/a	n/a	-US$45m
Dec 31 2023	US$2m	US$625k	-US$35m
Sep 30 2023	n/a	n/a	-US$34m
Jun 30 2023	n/a	n/a	-US$31m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$2m	US$157k	-US$27m
Sep 30 2022	n/a	n/a	-US$30m
Jun 30 2022	n/a	n/a	-US$30m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$256k	n/a	-US$25m

Compensatie versus markt: De totale vergoeding ($USD 2.07M ) Jim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 930.10K ).

Compensatie versus inkomsten: De vergoeding van Jim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Jim Corbett (66 yo)

2.2yrs

Tenure

US$2,068,675

Compensatie

Mr. James M. Corbett, also known as Jim, served as Chief Executive Officer of CathWorks Ltd. since October 27, 2017 until 2021. He serves as Director of CathWorks Ltd.until 2021. He served as an Independe...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
James Corbett	CEO, President & Executive Director	2.2yrs	US$2.07m	0.033% A$ 174.0k
David O'Toole	Chief Financial Officer	1.4yrs	US$2.18m	geen gegevens
David Fencil	Senior Vice President of Global Operations	1.8yrs	geen gegevens	geen gegevens
Katie Bush	Senior Vice President of Scientific & Medical Affairs	less than a year	geen gegevens	geen gegevens
Jessica Ekeberg	Investor Relations Executive	no data	geen gegevens	geen gegevens
Nicole Kelsey	Chief Legal & Compliance Officer and Corporate Secretary	less than a year	geen gegevens	geen gegevens
Debbie Garner	Senior Vice President of Global Marketing & Strategy	6.3yrs	geen gegevens	geen gegevens
Rob Hall	Senior Vice President of Human Resources	1.8yrs	geen gegevens	geen gegevens
Niraj Doshi	Senior Vice President of Product Development & Program Management	1.8yrs	geen gegevens	geen gegevens
Ron Lagerquist	Senior Vice President of Quality Assurance & Regulatory Affairs	1.8yrs	geen gegevens	geen gegevens
Robin VanDenburgh	Senior Vice President of U.S. Commercial Sales	less than a year	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van AVH wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
James Corbett	CEO, President & Executive Director	3.3yrs	US$2.07m	0.033% A$ 174.0k
Jan Reed	Independent Non-Executive Director	3.3yrs	US$211.12k	0.11% A$ 578.5k
Jeremy Curnock-Cook	Independent Non-Executive Director	12.1yrs	US$199.87k	0.079% A$ 412.7k
Fiona Wood	Founder and Member of Clinical Advisory Board	8.8yrs	US$29.80k	geen gegevens
Louis Panaccio	Independent Non-Executive Chairman	10.3yrs	US$234.69k	0.16% A$ 864.4k
Robert McNamara	Independent Non-Executive Director	1.6yrs	US$369.11k	0.075% A$ 393.1k
Cary Vance	Independent Non-Executive Director	1.6yrs	US$364.94k	0.037% A$ 192.9k
Suzanne Crowe	Independent Non-Executive Director	8.8yrs	US$195.28k	0.10% A$ 545.1k

6.1yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AVH wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).

AVITA Medical Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

AVITA Medical, Inc. Names Robin Vandenburgh as SVP of U.S. Commercial Sales

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc., Annual General Meeting, Jun 05, 2024

AVITA Medical, Inc. Announces Appointment of David O’Toole as Chief Financial Officer

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc., Annual General Meeting, Dec 12, 2022

Recent updates

AVITA Medical, Inc. Provides Financial Guidance for Fourth Quarter and Full Year of 2024

AVITA Medical, Inc. to Report Q3, 2024 Results on Nov 07, 2024

AVITA Medical, Inc. Provides Financial Guidance for Third Quarter 2024 and Updates Financial Guidance for Full Year 2024

AVITA Medical, Inc. Names Robin Vandenburgh as SVP of U.S. Commercial Sales

AVITA Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc. Announces FDA Approval of RECELL GO

AVITA Medical, Inc. Provides Earnings Guidance for the Second of 2024

AVITA Medical, Inc., Annual General Meeting, Jun 05, 2024

AVITA Medical, Inc. to Report Q3, 2024 Results on May 13, 2024

AVITA Medical, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

AVITA Medical, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Avita Medical, Inc. Provides Preliminary Revenue Guidance for Fourth Quarter and Full-Year 2023 and First Quarter and Year 2024

AVITA Medical, Inc. to Report Q3, 2023 Results on Nov 09, 2023

AVITA Medical, Inc. announced that it expects to receive $90 million in funding from OrbiMed Advisors LLC

New minor risk - Shareholder dilution

New minor risk - Profitability

AVITA Medical, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

Second quarter 2023 earnings released: US$0.082 loss per share (vs US$0.05 loss in 2Q 2022)

AVITA Medical, Inc. to Report Q2, 2023 Results on Aug 10, 2023

AVITA Medical, Inc. Submits FDA PMA Supplement for Recell Go

AVITA Medical, Inc. Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients

AVITA Medical, Inc. Announces Appointment of David O’Toole as Chief Financial Officer

AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects

First quarter 2023 earnings released: US$0.073 loss per share (vs US$0.076 loss in 1Q 2022)

AVITA Medical, Inc. Expects FDA Submission of Recell Go by June 30, 2023

AVITA Medical, Inc. Announces Executive Changes

Full year 2022 earnings released: US$0.21 loss per share (vs US$0.23 loss in FY 2021)

AVITA Medical, Inc. to Report Q4, 2022 Results on Feb 23, 2023

AVITA Medical, Inc. Submits FDA PMA Application for Vitiligo

AVITA Medical, Inc. Submits PMA Supplement for Soft Tissue Repair

Third quarter 2022 earnings released: US$0.045 loss per share (vs US$0.048 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.045 loss per share (vs US$0.048 loss in 3Q 2021)

AVITA Medical, Inc. Revises Financial Guidance for the Year 2022

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL System for Soft Tissue Repair

AVITA Medical, Inc. to Report Q3, 2022 Results on Nov 10, 2022

AVITA Medical, Inc., Annual General Meeting, Dec 12, 2022

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc. Announces Chief Executive Officer Changes

AVITA Medical, Inc. Announces Positive Topline Results from A Pivotal Randomized, Controlled Trial Evaluating the Safety and Effectiveness of the RECELL® System for Repigmentation of Stable Vitiligo Lesions

RECELL Insurance Coverage Begins in Japan for Acute Burns

Second quarter 2022 earnings released: US$0.05 loss per share (vs US$0.038 loss in 2Q 2021)

AVITA Medical, Inc. Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries Using the Recell System

AVITA Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

AVITA Medical, Inc.(NasdaqCM:RCEL) dropped from Russell 2000 Growth Index

Avita Medical, Inc. Provides Guidance for Year 2022

Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors

Forecast to breakeven in 2024

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

AVITA Medical, Inc. Provides Revenue Guidance for the Calendar Year 2022

AVITA (AVH) Announces RECELL Receives Japan PMDA Approval

AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use

AVITA Medical, Inc. to Report First Half, 2022 Results on Feb 28, 2022

Forecast to breakeven in 2024

AVITA Medical, Inc. Establishes Proof of Concept for Gene Therapy

Forecast to breakeven in 2024

AVITA Medical, Inc. Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo

First quarter 2022 earnings released: US$0.048 loss per share (vs US$0.095 loss in 1Q 2021)

Full year 2021 earnings released: US$0.23 loss per share (vs US$0.41 loss in FY 2020)

AVITA Medical, Inc. Provides Revenue Guidance for the First Quarter of Fiscal Year 2022

FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical, Inc.'s Pivotal Study of the RECELL® System for Vitiligo Treatment

AVITA Medical, Inc. Provides Revenue Guidance for the Fourth Quarter Ending June 30, 2021

Avita Medical, Inc. Announces Preliminary Unaudited Financial Results for the Fiscal Fourth Quarter Ending June 30, 2021

U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.053 loss per share (vs US$0.14 loss in 3Q 2020)

AVITA Medical, Inc. Provides Earnings Guidance for 2021

AVITA Medical, Inc. Will Not Provide Financial Guidance At This Time

AVITA Medical, Inc. to Report Q2, 2021 Results on Feb 11, 2021